| Literature DB >> 30567307 |
Michał Węgiel1,2, Artur Dziewierz3, Joanna Wojtasik-Bakalarz4, Danuta Sorysz5, Andrzej Surdacki6, Stanisław Bartuś7, Dariusz Dudek8,9, Tomasz Rakowski10.
Abstract
According to guidelines, it is safe for low-risk patients with myocardial infarction (MI) to be discharged within 72 h of hospitalization. However, results coming from registries show that the hospital stay is often much longer in a real-life situation. Data on the length of the hospital stay (LOS) of MI patients in Polish centers are lacking. We enrolled 212 consecutive patients with acute MI. Low-risk patients were defined according to PAMI II criteria: age <70 years, left ventricular ejection fraction (LVEF) >45%, no persistent ventricular arrhythmia, and no multi-vessel disease (MVD). The median of the hospitalization length was eight days (Q1: 6; Q3: 9). In low-risk patients (25%), the median of LOS was six days (Q1: 5; Q3: 7) (p < 0.001). In a logistic regression analysis patients age, LVEF, ST-segment-elevation MI and the presence of MVD were independent predictors of longer hospitals stay (≥8 days). During follow up, there were no significant differences in the rates of clinical events between patients with shorter (<8 days) and longer (≥8 days) hospitalization. In a real-life situation, the LOS, even in low-risk patients is much longer than recommended in the guidelines.Entities:
Keywords: follow up; hospitalization length; myocardial infarction; predictors
Year: 2018 PMID: 30567307 PMCID: PMC6306951 DOI: 10.3390/jcm7120564
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flow chart of patients entering the study. 1 myocardial infarction; 2 myocardial infarction without obstructive coronary arteries; 3 coronary-artery bypass grafting; 4 length of hospital stay.
Baseline and in-hospital clinical characteristics.
| Patients Surviving until Hospital Discharge ( | All Patients ( | |||||
|---|---|---|---|---|---|---|
| LOS 8 <8 Days (92 Patients) | LOS ≥8 Days (98 Patients) | Higher-Risk (158 Patients) | Low-Risk (54 Patients) | |||
|
| ||||||
| ST-elevation MI 1 (%) | 22 | 37 | 0.03 | 33 | 24 | 0.24 |
| Age (years) | 64 ± 11 | 69 ± 12 | 0.003 | 71±11 | 57 ± 8 | <0.001 |
| Male gender (%) | 71 | 64 | 0.36 | 63 | 76 | 0.097 |
| Hypertension history (%) | 82 | 82 | 1.0 | 79 | 78 | 0.85 |
| Diabetes history (%) | 29 | 41 | 0.13 | 41 | 24 | 0.03 |
| COPD history 2 (%) | 9 | 14 | 0.26 | 13 | 7 | 0.45 |
| Smoking (%) | 48 | 45 | 0.77 | 38 | 65 | 0.001 |
| Stroke history (%) | 8 | 11 | 0.46 | 11 | 2 | 0.048 |
| MI history (%) | 29 | 23 | 0.41 | 27 | 22 | 0.59 |
|
| ||||||
| LVEF 3 (%) | 55 (Q1: 45; Q3: 60) | 45 (Q1: 38; Q3: 55) | <0.001 | 45 (Q1: 37 Q3: 52) | 56 (Q1: 50 Q3: 60) | <0.001 |
| LAD 4 culprit (%) | 29 | 40 | 0.17 | 39 | 30 | 0.25 |
| Multi-vessel disease (%) | 23 | 48 | <0.001 | 48 | 0 | <0.001 |
| Staged revascularization (%) | 14 | 33 | 0.003 | 28 | 4 | <0.001 |
| Ventricular arrhythmia (%) | 9 | 16 | 0.13 | 11 | 0 | 0.008 |
| GFR 5 (mL/min/1.73 m2) | 85 ± 28 | 77 ± 34 | 0.08 | 72 ± 33 | 92 ± 23 | <0.001 |
| RBC 6 transfusion (%) | 2 | 4 | 0.68 | 4 | 2 | 0.68 |
| Respiratory infections (%) | 6 | 20 | 0.006 | 19 | 6 | 0.017 |
| ACEI/ARB 7 (%) | 88 | 88 | 1.0 | 78 | 91 | 0.04 |
| B-blocker (%) | 88 | 90 | 0.82 | 80 | 89 | 0.21 |
| Loop diuretics (%) | 24 | 42 | 0.009 | 47 | 9 | <0.001 |
| Aldosterone antagonists (%) | 13 | 33 | 0.002 | 28 | 6 | <0.001 |
1 myocardial infarction; 2 chronic obstructive pulmonary disease; 3 left ventricular ejection fraction; 4 left anterior descending artery; 5 glomerular filtration rate; 6 red blood cell; 7 angiotensin converting enzyme inhibitor, angiotensin receptor blocker, 8 length of hospital stay.
Figure 2Histogram of length of hospital stays in low-risk patients (A) and higher-risk patients (B).
Baseline and in-hospital clinical characteristics in relation to the type of myocardial infarction.
| ST-Elevation MI 1 (65 Patients) | Non-ST-Elevation MI (147 Patients) | ||
|---|---|---|---|
|
| |||
| Age (years) | 67 ± 13 | 67 ± 11 | 0.93 |
| Male gender (%) | 60 | 69 | 0.21 |
| Hypertension history (%) | 71 | 82 | 0.07 |
| Diabetes history (%) | 35 | 37 | 0.88 |
| COPD history 2 (%) | 11 | 12 | 1.0 |
| Smoking (%) | 48 | 43 | 0.65 |
| Stroke history (%) | 6 | 9 | 0.59 |
| MI history (%) | 12 | 31 | 0.003 |
| Low-risk (%) | 20 | 28 | 0.24 |
|
| |||
| Length of hospital stay (d) | 8 (Q1: 7; Q3: 9) | 7 (Q1: 6; Q3: 10) | 0.19 |
| LVEF 3 (%) | 45 (Q1: 38; Q3: 55) | 50 (Q1: 40; Q3: 55) | 0.14 |
| LAD 4 culprit (%) | 45 | 33 | 0.12 |
| Multi-vessel disease (%) | 31 | 38 | 0.35 |
| Staged revascularization (%) | 20 | 22 | 0.86 |
| Ventricular arrhythmia (%) | 11 | 7 | 0.41 |
| GFR 5 (mL/min/1.73 m2) | 87 ± 35 | 73 ± 30 | 0.006 |
| RBC 6 transfusion (%) | 5 | 3 | 0.7 |
| Respiratory infections (%) | 15 | 16 | 1.0 |
| ACEI/ARB 7 (%) | 78 | 83 | 0.44 |
| B-blocker (%) | 80 | 84 | 0.56 |
| Loop diuretics (%) | 36 | 38 | 0.76 |
| Aldosterone antagonists (%) | 31 | 18 | 0.04 |
1 myocardial infarction; 2 chronic obstructive pulmonary disease; 3 left ventricular ejection fraction; 4 left anterior descending artery; 5 glomerular filtration rate; 6 red blood cell; 7 angiotensin converting enzyme inhibitor, angiotensin receptor blocker.
Baseline and in-hospital clinical characteristics in relation to the presence of multi-vessel diseases.
| Multi-Vessel Disease (76 Patients) | No Multi-Vessel Disease (136 Patients) | ||
|---|---|---|---|
|
| |||
| ST-elevation MI 1 (%) | 26 | 33 | 0.35 |
| Age (years) | 67 ± 10 | 67 ± 12 | 0.72 |
| Male gender (%) | 71 | 64 | 0.36 |
| Hypertension history (%) | 72 | 82 | 0.11 |
| Diabetes history (%) | 41 | 34 | 0.37 |
| COPD history 2 (%) | 8 | 13 | 0.27 |
| Smoking (%) | 46 | 44 | 0.89 |
| Stroke history (%) | 7 | 10 | 0.61 |
| MI history (%) | 24 | 26 | 0.74 |
| Low-risk (%) | 0 | 40 | <0.001 |
|
| |||
| Length of hospital stay (d) | 8 (Q1: 7; Q3: 10) | 7 (Q1: 5; Q3: 9) | <0.001 |
| LVEF 3 (%) | 45 (Q1: 39; Q3: 55) | 50 (Q1: 40; Q3: 58) | 0.14 |
| LAD 4 culprit (%) | 34 | 38 | 0.66 |
| Staged revascularization (%) | 54 | 4 | <0.001 |
| Ventricular arrhythmia (%) | 9 | 7 | 0.61 |
| GFR 5 (mL/min/1.73 m2) | 81 ± 35 | 76 ± 30 | 0.31 |
| RBC 6 transfusion (%) | 3 | 4 | 0.71 |
| Respiratory infections (%) | 16 | 15 | 1.0 |
| ACEI/ARB 7 (%) | 77 | 84 | 0.27 |
| B-blocker (%) | 83 | 82 | 1.0 |
| Loop diuretics (%) | 33 | 40 | 0.37 |
| Aldosterone antagonists (%) | 17 | 24 | 0.29 |
1 myocardial infarction; 2 chronic obstructive pulmonary disease; 3 left ventricular ejection fraction; 4 left anterior descending artery; 5 glomerular filtration rate; 6 red blood cell; 7 angiotensin converting enzyme inhibitor, angiotensin receptor blocker.
Logistic regression model for predicting hospitalization lengths ≥8 days.
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| OR 7 | 95% CI 8 | OR | 95% CI | |||
|
| ||||||
| Age (per one year increase) | 1.04 | 1.01–1.07 | 0.004 | 1.04 | 1.01–1.07 | 0.016 |
| Female gender | 1.3 | 0.7–2.4 | 0.35 | |||
| Arterial hypertension | 1.0 | 0.48–2.1 | 0.98 | |||
| Diabetes mellitus | 1.7 | 0.91–3.0 | 0.1 | |||
| History of MI 1 | 0.74 | 0.4–1.4 | 0.36 | |||
| History of CABG 2 | 0.69 | 0.15–3.2 | 0.64 | |||
| History of stroke | 1.5 | 0.57–4.1 | 0.4 | |||
| Smoking | 0.89 | 0.5–1.6 | 0.69 | |||
| Hyperlipidemia | 0.87 | 0.47–1.6 | 0.64 | |||
| COPD 3 | 1.75 | 0.7–4.4 | 0.23 | |||
| Atrial fibrillation | 2.1 | 0.97–4.7 | 0.06 | |||
| Hemodialysis | 1.9 | 0.34–10.7 | 0.46 | |||
|
| ||||||
| ST-elevation MI | 2.09 | 1.1–4.0 | 0.025 | 2.3 | 1.1–4.7 | 0.02 |
| LVEF 4 (per 1% increase) | 0.95 | 0.93–0.98 | 0.001 | 0.97 | 0.94–0.99 | 0.016 |
| Multi-vessel disease | 3.1 | 1.7–5.8 | <0.001 | 3.4 | 1.7–6.6 | <0.001 |
| Ventricular arrhythmia | 2.2 | 0.7–7.5 | 0.2 | |||
| RBC 5 transfusion | 1.9 | 0.3–10.7 | 0.46 | |||
| Pneumonia | 3.7 | 1.4– 9.6 | 0.008 | |||
| GFR 6 (per 1 mL/min/1.73 m2 increase) | 0.9 | 0.98–1.0 | 0.09 | |||
Cox Snell R2 = 0.17; Nagelkerke R2 = 0.23; Hosmer Lemoshow test p = 0.33. 1 myocardial infarction; 2 coronary-artery bypass grafting; 3 chronic obstructive pulmonary disease; 4 left ventricular ejection fraction; 5 red blood cell; 6 glomerular filtration rate; 7 odds ratio; 8 confidence interval.
Rates of events occurring during the hospital stay and follow-up.
| Patients Surviving until Hospital Discharge ( | All Patients ( | |||||
|---|---|---|---|---|---|---|
| LOS 2 <8 Days (92 Patients) | LOS ≥8 Days (98 Patients) | Higher-Risk (158 Patients) | Low-Risk (54 Patients) | |||
|
| ||||||
| All-cause mortality (%) | - | - | - | 14 | 0 | 0.001 |
| Cardiovascular mortality (%) | - | - | - | 14 | 0 | 0.001 |
| All recurrent MI 1 (%) | 0 | 0 | - | 0 | 0 | - |
| Non-fatal recurrent MI (%) | 0 | 0 | - | 0 | 0 | - |
| All stroke (%) | 1 | 1 | 1.0 | 2 | 0 | 0.57 |
| Non-fatal stroke (%) | 1 | 1 | 1.0 | 1 | 0 | 1.0 |
| Combined endpoint (%) | 1 | 1 | 1.0 | 15 | 0 | 0.001 |
|
| ||||||
| All-cause mortality (%) | 4 | 4 | 1.0 | 18 | 2 | 0.001 |
| Cardiovascular mortality (%) | 0 | 2 | 0.5 | 15 | 0 | 0.001 |
| All recurrent MI (%) | 11 | 7 | 0.45 | 8 | 9 | 0.77 |
| Non-fatal recurrent MI (%) | 11 | 6 | 0.3 | 7 | 9 | 0.56 |
| All stroke (%) | 2 | 2 | 1.0 | 4 | 0 | 0.34 |
| Non-fatal stroke (%) | 2 | 2 | 1.0 | 2 | 0 | 0.57 |
| Combined endpoint (%) | 12 | 10 | 0.82 | 24 | 9 | 0.02 |
1 myocardial infarction; 2 length of hospital stay.
Figure 3Kaplan–Meier survival analysis for general survival, and survival without combined endpoint in relation to risk (A,B) and hospitalization length categories (C,D).